Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Cancer_Deg

Financiado

Cerrado

Deciphering regulatory principles of proteasome heterogeneity and the degradatio...

Deciphering regulatory principles of proteasome heterogeneity and the degradation landscape in cancer Proteasome activity is crucial to removal of defective or obsolete proteins, cell signaling and antigen presentation. In cancer, proteasomal degradation was shown to play key roles in tumor growth, antigenicity and response to imm... ver más

31/07/2027

WEIZMANN

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-07-25

ERC-2021-COG: ERC CONSOLIDATOR GRANTS Scope:Objectives

I+D

Cerrada hace 3 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

WEIZMANN

1.98M€ | Lider

Proyectos interesantes

Proteasome in cancer

Medical Technol...

Data Science

146K€ Cerrado

ImmunoFit

Medical Technol...

Data Science

2M€ Cerrado

ProteaSys

Medical Technol...

Data Science

1M€ Cerrado

SpatialTMEMetabolism

Medical Technol...

Data Science

1M€ Cerrado

UTILIUM

Medical Technol...

Data Science

200K€ Cerrado

CANCER-DC

Medical Technol...

Data Science

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 60 meses Fecha Inicio: 2022-07-25
Fecha Fin: 2027-07-31

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Proteasome activity is crucial to removal of defective or obsolete proteins, cell signaling and antigen presentation. In cancer, proteasomal degradation was shown to play key roles in tumor growth, antigenicity and response to immunotherapy. Yet, comprehensive analysis of proteasome subunit composition and the degradation landscape in cancer has not been performed to date, rendering our understanding of inter-patient proteasome heterogeneity and proteasome-dependent mechanisms underlying tumor-immune interactions far from complete. Our novel, unbiased approach, MAPP, for MS Analysis of Proteasome-cleaved Peptides, is ideally suited to examine the missing link between cellular degradation and cancer immunity. We have already demonstrated its utility in identifying degradation events associated with inflammation, proteasome cleavage, substrate alterations and an anti-inflammatory role of the proteasome subunit PSME4, in lung cancer. We aim to capitalize on our powerful analytical methods, vast experience and preliminary data and develop further our cutting-edge technology, to shed light on the uncharted area of degradation pathways in cancer. We plan to: (1) Characterize both proteasome composition and the degradation landscape across cancer types and develop MAPP further to enable in vivo, tissue-specific, and proteasome-type-specific profiling. We strive to provide a near complete narrative of proteasome activity and distribution in tumors and their role in shaping tumor-immune interactions. (2) Study proteasome-dependent mechanisms underlying tumor immunogenicity and response to immunotherapy at the biochemical, cellular and physiological levels. (3) Exploit inter-patient proteasome heterogeneity for translational opportunities, in particular as an adjunct to current immunotherapies. Cancer_Deg will transform our understanding of proteasomal degradation in cancer, with important implications for numerous diseases, precision oncology and drug discovery.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores